Evoke Pharma, Inc.
EVOK
$3.30
$0.216.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 97.40% | 69.83% | 125.51% | 114.15% | 110.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.40% | 69.83% | 125.51% | 114.15% | 110.45% |
| Cost of Revenue | 100.85% | 197.99% | -27.70% | 82.81% | -68.96% |
| Gross Profit | 97.27% | 66.90% | 133.70% | 116.24% | 166.70% |
| SG&A Expenses | 25.88% | 22.12% | 34.97% | 10.24% | 52.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.33% | 24.43% | 29.46% | 9.15% | 42.20% |
| Operating Income | 36.77% | 19.81% | 31.43% | 30.34% | -10.42% |
| Income Before Tax | 39.98% | 22.52% | 32.16% | 29.57% | -10.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.98% | 22.52% | 32.16% | 29.57% | -10.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.98% | 22.52% | 32.16% | 29.57% | -10.22% |
| EBIT | 36.77% | 19.81% | 31.43% | 30.34% | -10.42% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 95.19% | 84.58% | 86.50% | 74.07% | -10.18% |
| Normalized Basic EPS | 95.19% | 84.58% | 86.50% | 74.07% | -10.18% |
| EPS Diluted | 95.19% | 84.58% | 86.50% | 74.07% | -10.18% |
| Normalized Diluted EPS | 95.19% | 84.58% | 86.50% | 74.07% | -10.18% |
| Average Basic Shares Outstanding | 1,147.38% | 402.48% | 402.48% | 171.64% | 0.04% |
| Average Diluted Shares Outstanding | 1,147.38% | 402.48% | 402.48% | 171.64% | 0.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |